Sabitlenmiş Tweet
First look at Phase 1b data for ENV-294 in atopic dermatitis.
Small study, but interesting signal 👇
#clinicaldata #atopicdermatitis #eczema #AIbiotech
English
Enveda
303 posts
Enveda
@enveda
Engineering new drugs from nature with knowledge graphs, metabolomics, and ML
Boulder, CO Katılım Aralık 2020
94 Takip Edilen2.3K Takipçiler
The promise of AI to discover medicines that will fundamentally change how we live is happening NOW.
Enveda is using AI to analyze biology and chemistry at an unprecedented resolution, unlocking new possibilities for drug discovery that have the potential to transform health and humanity.
Don't miss Enveda's Chief Execution Officer, @danwee08, speaking at the inaugural LEAP East conference in Hong Kong next week.
July 9 | 10:10 - 10:40 AM
The Next Frontier for Therapeutics: AI Driven Innovation | Orbital Stage | LEAP East
leapeast.com/events/2026-ag…
#DrugDiscovery #AI #Biotech
English
How has Enveda defied convention in both AI and biotech to quickly become a clinical-stage company with multiple drugs in patients?
Our Founder & CEO, @viswacolluru, recently sat down with Akshay Rai at @PremjiInvest, a high-conviction investor who has backed Enveda across multiple rounds, to discuss the strategies that have shaped Enveda's approach. Some of the topics they explore:
On AI: Why applying AI to the same target-first playbook may not be enough to change drug discovery's 90% failure rate.
On speed and efficiency: How Enveda built an integrated prediction, validation, and iteration loop that dramatically accelerates the path from hit to candidate.
On defensibility: Why the most valuable medicines may be the ones that reveal entirely new biology.
On vision: What it might take to build a generational pharma company rather than optimize for a single-asset outcome.
See the full interview: premjiinvest.com/blog/ceo-serie…
#Biotech #DrugDiscovery #AI
English
The next generation of medicines requires us to rethink how we discover, develop, fund, and deliver innovation.
At #BIO2026, Enveda leaders Founder & CEO @viswacolluru, Chief Scientific Officer Hannah Gordon @brieski, and SVP of Capital Formation & Global Partnerships, Bigyan R. Bista, PhD will help shape the conversation around some of the most important questions facing our industry.
• What if we could compress the timeline from scientific discovery to patient impact?
• What does it take to build investor conviction around an ambitious vision in today's market?
• How are AI and nature unlocking signals that have remained hidden for centuries?
• What global partnerships are needed to bring breakthrough medicines faster to patients in need?
Connect with us at #BIO2026. convention.bio.org/program/2026-p…
Link in the comments.
#DrugDiscovery #Biotech #AI
English
At today's pace, humanity will wait more than 500 years for every known disease to have a cure.
What would our industry do differently if we acted as though we had 50?
At #BIO2026, Enveda Founder & CEO @viswacolluru will join biotech leaders for a private event on what it will take to dramatically compress the timeline from scientific discovery to patient impact.
The conversation will explore where AI can meaningfully accelerate drug discovery, the barriers slowing progress today, and what the future could look like if our industry truly optimized for getting medicines to patients faster.
June 23 | 6:00 - 9:00 PM: From 500 years to 50 - accelerating cures | Alpha Hours / 01 luma.com/kjce7vst
#DrugDiscovery #Biotech #AI
English
What if the next generation of medicines is already encoded in biology?
At #BIO2026, Enveda’s Chief Scientific Officer Hannah Gordon, PhD @brieski will discuss how AI is helping researchers uncover biological signals that have remained hidden for centuries, transforming how medicines are discovered in the process.
June 24 | PM: AI x Nature: Unlocking Biology's Hidden Blueprint for the Next Generation of Medicines
convention.bio.org/2026-sessions-…
From closing the loop between computation and experimentation to uncovering targets that have long eluded traditional R&D, the conversation will explore how AI and biology are reshaping the future of drug discovery.
If you're attending BIO, join the conversation.
#AI #DrugDiscovery #Biotech
English
The future of biotech won't be shaped by great science alone. It will be shaped by who we choose to build with and the people we build for.
At #BIO2026, Enveda's Senior Vice President of Capital Formation & Global Partnerships, Bigyan R. Bista, PhD will be exploring the power of collaboration from two different angles.
June 24 | 11:00 AM: Bridging Borders: How US-Asia Collaboration Is Redefining Global Biotech Deal-Making
Cross-border partnerships are reshaping how companies access innovation, capital, and expertise. This session explores the evolving models driving the next generation of global biotech collaboration and what they mean for companies building the pipelines of the future. convention.bio.org/2026-sessions-…
June 25 | 9:00 AM: Patients: Our Innovation and Advocacy Partners
From discovery through development and access, patient perspectives play a critical role in shaping better medicines. This discussion focuses on practical approaches for embedding the patient voice throughout the innovation journey, not as a values statement, but as a design principle. convention.bio.org/2026-sessions-…
#BIO2026 #Biotech #DrugDiscovery #PatientAdvocacy
English
What does it take to raise $100M+ in a market where capital is more selective than ever?
At #BIO2026, Enveda Founder & CEO @viswacolluru will join @ky_lahucik of @endpts alongside biotech executives who have successfully closed some of the industry's largest financings in a challenging market.
Viswa will share a rare look at how Enveda earned investor conviction around an ambitious vision: turning nature's chemistry into the next generation of first-in-class medicines. He’ll discuss the decisions, milestones, and long-term thinking required to build a company for decades, not just the next financing round.
June 25 | 9:00 AM
Breaking the $100M Barrier: How Biotechs Closed Mega-Rounds in a Tough Market
convention.bio.org/2026-sessions-…
#BIO2026 #BiotechFunding #DrugDiscovery
English
Hannah Gordon, PhD, MSCI (@brieski) just made the Top 100 Women in AI list, and we couldn't be more proud!
As Enveda's Chief Scientific Officer, Hannah steers the pipeline, translating the chemical complexity of nature into a new generation of first-in-class medicines. She brings scientific depth and vision to deploy AI with one goal in mind: maximum impact for patients.
This list celebrates an exceptional cross-industry cohort of women defining the AI era, leading with purpose, and shaping the future.
Congratulations to all the honorees. Read more from XFactor Ventures and Flybridge here: 100womeninai.com/hannah-gordon
#100WomenInAI #WomenInAI #ArtificialIntelligence
English
Enveda retweetledi
Metabolomics folks: if you're at #ASMS, stop by Enveda's posters to get sneak peeks of our impending data drop and our upcoming public CASMI small molecule identification competition!
Wednesday: WP 439 (Enveda-180 dataset)
hursday: ThP 341 (CASMI 2016)
English
Enveda retweetledi
Misaligned incentives hold big companies back from making the kind of bets that actually change the world.
This clip from @viswacolluru was an awesome explainer on how prevailing wisdom on obesity held back GLP-1s from hitting primetime & how to do it differently @enveda
English
The potential of #AI in #DrugDiscovery has been discussed for a while, with little to show for it in the clinic.
Enveda is changing that. Positive clinical readout, multiple mega-blockbuster clinical pipeline, and a platform that is expanding our understanding of biology through chemistry.
Our Founder & CEO, @viswacolluru, will present at the @UBS Private Biotech Innovation Summit on May 18, one of the most selective investor forums for private biopharma companies.
Clinical proof that our AI-native platform can produce differentiated medicines at scale, not just interesting molecules. See you there!
English
Enveda retweetledi
We're running a metabolomics experiment at @EdgeEsmeralda this June 🧬
@enveda is giving 15 to 20 residents free mass spec profiling of hundreds of metabolites in their blood across a week, plus optional cold plunge and sauna response sampling.
More below ↓
Edge City@JoinEdgeCity
English
We’ve built the world’s first Chemical Sequencer, but unlocking nature’s chemistry still requires more data and better ways to understand it. That’s why we’re deepening our collaboration with @tomas_pluskal and his lab at @IOCBPrague, a global leader in natural product chemistry and plant #metabolomics.
We’re proud to support the PhD work of Filip Jozefov, whose research combines machine learning and mass spectrometry. Filip is developing new machine learning approaches using a rich dataset generated in the lab. These approaches improve the accuracy of molecular structure prediction, which is an essential step toward decoding nature’s chemistry at scale.
Our ongoing collaboration supports our commitment towards advancing cutting-edge science, pushing the boundaries of what’s possible in structure prediction, and helping to shape the future direction of the field.🚀
#MachineLearning #MassSpectrometry #DrugDiscovery #Biotech
English
Enveda retweetledi
Season four of Invest in Progress starts here. 🎙️ Tom Slater sits down with @ViswaColluru of Enveda @enveda on using AI to unlock nature’s chemistry and search for the next generation of medicines. 💊 Listen now: linktr.ee/InvestInProgre…
English
Enveda retweetledi
.@viswacolluru thinks most ideas that change the trajectory of human life are actually old. The locomotive was first a steam engine. Electric cars, neural networks, and rockets all existed long before the world caught up to them.
The question is not what to invent but which abandoned idea the world is finally ready to revisit, where the ancillary technologies have matured enough to clear the original constraints.
For Viswa, that idea is using plant compounds as the starting point for drug discovery. The pharma industry set it aside, and he is revisiting it.
Mario Gabriele@mariogabriele
For decades, drug discovery has shifted away from nature and toward biology-first approaches. @viswacolluru believes that shift was a catastrophic mistake. His company, Enveda (@enveda), has raised over $500 million to build a “search engine for nature’s chemistry.” In our conversation, we explore: • Why the pharmaceutical industry abandoned nature (and why that was a massive mistake) • How Enveda built a system to decode unknown molecules in nature • The deeply personal story of his mother’s battle with leukemia and how it shaped his life’s work • Why old ideas, from immunotherapy to natural products, often hold the most latent potential • How Enveda developed 18 drug candidates for about $1 million each instead of $10-15 million • Enveda’s three leading drug candidates targeting eczema, obesity, and ulcerative colitis • Why first-in-class medicines capture the vast majority of returns in pharma • What competitive table tennis taught him about building companies Thank you to the partners who make this possible @brexHQ: The intelligent finance platform: brex.com/mario @ahrefs Brand Radar: Find your brand in AI results: ahrefs.com/generalist @withpersona: Trusted identity verification for any use case: withpersona.com/generalist (00:00) Introduction to Viswa Colluru (07:06) Early pull toward technology (14:24) Studying Biotechnology (24:23) Innovation vs. novelty (32:05) Joining Recursion (40:42) What launched Enveda (49:53) Chemistry-first approach (52:17) Raising $225K and investing $55K personally (56:04) Initial studies and targets (1:18:27) Enveda’s long-term vision (1:21:31) Book recommendation
English
Enveda retweetledi
Pharma spent 30 years going biology-first. Enveda is built on the opposite bet.
On @generalist with @mariodgabriele: why the chemistry 4 billion years of evolution has already selected for is still the best starting material we have ...and why that question is personal for me.
Mario Gabriele@mariogabriele
For decades, drug discovery has shifted away from nature and toward biology-first approaches. @viswacolluru believes that shift was a catastrophic mistake. His company, Enveda (@enveda), has raised over $500 million to build a “search engine for nature’s chemistry.” In our conversation, we explore: • Why the pharmaceutical industry abandoned nature (and why that was a massive mistake) • How Enveda built a system to decode unknown molecules in nature • The deeply personal story of his mother’s battle with leukemia and how it shaped his life’s work • Why old ideas, from immunotherapy to natural products, often hold the most latent potential • How Enveda developed 18 drug candidates for about $1 million each instead of $10-15 million • Enveda’s three leading drug candidates targeting eczema, obesity, and ulcerative colitis • Why first-in-class medicines capture the vast majority of returns in pharma • What competitive table tennis taught him about building companies Thank you to the partners who make this possible @brexHQ: The intelligent finance platform: brex.com/mario @ahrefs Brand Radar: Find your brand in AI results: ahrefs.com/generalist @withpersona: Trusted identity verification for any use case: withpersona.com/generalist (00:00) Introduction to Viswa Colluru (07:06) Early pull toward technology (14:24) Studying Biotechnology (24:23) Innovation vs. novelty (32:05) Joining Recursion (40:42) What launched Enveda (49:53) Chemistry-first approach (52:17) Raising $225K and investing $55K personally (56:04) Initial studies and targets (1:18:27) Enveda’s long-term vision (1:21:31) Book recommendation
English